N-Boc-piperazine-2-amidoanhydride | 173774-50-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Boc-piperazine-2-amidoanhydride
• 英文别名: 1,1-Dimethylethyl (8aR)-tetrahydro-1,3-dioxo-3H-oxazolo[3,4-a]pyrazine-7(1H)-carboxylate；tert-butyl (8aR)-1,3-dioxo-5,6,8,8a-tetrahydro-[1,3]oxazolo[3,4-a]pyrazine-7-carboxylate
• CAS: 173774-50-0
• 化学式: C₁₁H₁₆N₂O₅
• 分子量: 256.258
• InChiKey: CVUUXSUZZICPSM-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  76.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-Boc-piperazine-2-amidoanhydride 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 48.0h， 以50%的产率得到(R)-1-BOC-3-羟甲基哌嗪
  参考文献：
  名称：

  FARNESYL PROTEIN TRANSFERASE INHIBITORS

  摘要：

  公开号：

  EP1140904B1
• 作为产物：
  描述：

  (R)-1-n-boc-4-n-boc-哌嗪-2-羧酸 在 吡啶 、 氯化亚砜 作用下， 以 DMF (N,N-dimethyl-formamide) 、 乙腈 为溶剂， 反应 18.0h， 生成 N-Boc-piperazine-2-amidoanhydride
  参考文献：
  名称：

  NOVEL INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE

  摘要：

  公开号：

  EP1140909B1

文献信息

• 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
  申请人：SCHERING CORPORATION

  公开号：US20040138226A1

  公开（公告）日：2004-07-15

  In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17&bgr;-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17&bgr;-hydroxysteroid dehydrogenase using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一类新型化合物，作为第3型17β-羟基类固醇脱氢酶的抑制剂，以及制备这种化合物的方法，含有一种或多种这种化合物的药物组合物，制备含有一种或多种这种化合物的药物制剂的方法，以及使用这种化合物或药物组合物进行治疗、预防、抑制或改善与第3型17β-羟基类固醇脱氢酶相关的一种或多种疾病的方法。
• WO2007/84498
  申请人：——

  公开号：——

  公开（公告）日：——
• Farnesyl protein transferase inhibitors
  申请人：Kelly M. Joseph

  公开号：US20070213340A1

  公开（公告）日：2007-09-13

  Disclosed are compounds of the formula: wherein R 13 represents an imidazole ring; R 14 represents a carbamate, urea, amide or sulfonamide group, and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.
• 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
  申请人：Guzi J. Timothy

  公开号：US20080004248A1

  公开（公告）日：2008-01-03

  In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17β-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with type 3 17β-hydroxysteroid dehydrogenase using such compounds or pharmaceutical compositions.
• US7432268B2
  申请人：——

  公开号：US7432268B2

  公开（公告）日：2008-10-07